{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dwivedi P"],"funding":["National Institute of Environmental Health Sciences","NCRR NIH HHS","NIEHS NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["e1900144"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7492401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(5)"],"pubmed_abstract":["<h4>Purpose</h4>To evaluate cellular protein changes in response to treatment with an approved drug, ibrutinib, in cells expressing normal or mutated granulocyte-colony stimulating factor receptor (G-CSFR). G-CSFR mutations are associated with some hematological malignancies. Previous studies show the efficacy of ibrutinib (a Bruton's tyrosine kinase inhibitor) in mutated G-CSFR leukemia models but do not address broader signaling mechanisms.<h4>Experimental design</h4>A label-free quantitative proteomics workflow to evaluate the cellular effects of ibrutinib treatment is established. This includes three biological replicates of normal and mutated G-CSFR expressed in a mouse progenitor cell (32D cell line) with and without ibrutinib treatment.<h4>Results</h4>The proteomics dataset shows ab"],"journal":["Proteomics. Clinical applications"],"pubmed_title":["SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling."],"pmcid":["PMC7492401"],"funding_grant_id":["1S10 RR027015‐01","CA196658","R01 CA196658","ES007250","S10 RR027015","1S10 RR027015-01","P30 ES006096","T32 ES007250"],"pubmed_authors":["Grimes HL","Muench DE","Chutipongtanate S","Greis KD","Dwivedi P","Azam M"],"additional_accession":[]},"is_claimable":false,"name":"SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.","description":"<h4>Purpose</h4>To evaluate cellular protein changes in response to treatment with an approved drug, ibrutinib, in cells expressing normal or mutated granulocyte-colony stimulating factor receptor (G-CSFR). G-CSFR mutations are associated with some hematological malignancies. Previous studies show the efficacy of ibrutinib (a Bruton's tyrosine kinase inhibitor) in mutated G-CSFR leukemia models but do not address broader signaling mechanisms.<h4>Experimental design</h4>A label-free quantitative proteomics workflow to evaluate the cellular effects of ibrutinib treatment is established. This includes three biological replicates of normal and mutated G-CSFR expressed in a mouse progenitor cell (32D cell line) with and without ibrutinib treatment.<h4>Results</h4>The proteomics dataset shows ab","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2026-05-07T15:20:04.364Z","creation":"2022-02-11T10:00:15.66Z"},"accession":"S-EPMC7492401","cross_references":{"pubmed":["32319217"],"doi":["10.1002/prca.201900144"]}}